Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.
IPO Year: 2020
Exchange: NASDAQ
Website: kerostx.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
1/21/2025 | Overweight → Neutral | Cantor Fitzgerald | |
1/17/2025 | $15.00 | Outperform → Neutral | Wedbush |
12/16/2024 | $102.00 → $63.00 | Outperform | Oppenheimer |
12/16/2024 | Buy → Neutral | Guggenheim | |
12/13/2024 | $100.00 → $47.00 | Buy | H.C. Wainwright |
12/12/2024 | Buy → Hold | TD Cowen | |
12/12/2024 | Outperform → Mkt Perform | William Blair | |
12/12/2024 | Buy → Neutral | BTIG Research | |
11/5/2024 | Buy | Jefferies | |
10/24/2024 | Overweight | Cantor Fitzgerald |
8-K - Keros Therapeutics, Inc. (0001664710) (Filer)
DEFA14A - Keros Therapeutics, Inc. (0001664710) (Filer)
DEFA14A - Keros Therapeutics, Inc. (0001664710) (Filer)
DEFA14A - Keros Therapeutics, Inc. (0001664710) (Filer)
DEFA14A - Keros Therapeutics, Inc. (0001664710) (Filer)
8-K - Keros Therapeutics, Inc. (0001664710) (Filer)
10-Q - Keros Therapeutics, Inc. (0001664710) (Filer)
8-K - Keros Therapeutics, Inc. (0001664710) (Filer)
SCHEDULE 13G/A - Keros Therapeutics, Inc. (0001664710) (Subject)
SCHEDULE 13G - Keros Therapeutics, Inc. (0001664710) (Subject)
4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
SC 13G/A - Keros Therapeutics, Inc. (0001664710) (Subject)
SC 13G/A - Keros Therapeutics, Inc. (0001664710) (Subject)
SC 13G/A - Keros Therapeutics, Inc. (0001664710) (Subject)
SC 13D/A - Keros Therapeutics, Inc. (0001664710) (Subject)
SC 13G/A - Keros Therapeutics, Inc. (0001664710) (Subject)
SC 13G/A - Keros Therapeutics, Inc. (0001664710) (Subject)
SC 13G/A - Keros Therapeutics, Inc. (0001664710) (Subject)
SC 13G/A - Keros Therapeutics, Inc. (0001664710) (Subject)
SC 13G/A - Keros Therapeutics, Inc. (0001664710) (Subject)
SC 13D/A - Keros Therapeutics, Inc. (0001664710) (Subject)
4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
3 - Keros Therapeutics, Inc. (0001664710) (Issuer)
4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
4/A - Keros Therapeutics, Inc. (0001664710) (Issuer)
4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
3 - Keros Therapeutics, Inc. (0001664710) (Issuer)
4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
Cantor Fitzgerald downgraded Keros Therapeutics from Overweight to Neutral
Wedbush downgraded Keros Therapeutics from Outperform to Neutral and set a new price target of $15.00
Oppenheimer reiterated coverage of Keros Therapeutics with a rating of Outperform and set a new price target of $63.00 from $102.00 previously
Guggenheim downgraded Keros Therapeutics from Buy to Neutral
H.C. Wainwright reiterated coverage of Keros Therapeutics with a rating of Buy and set a new price target of $47.00 from $100.00 previously
TD Cowen downgraded Keros Therapeutics from Buy to Hold
William Blair downgraded Keros Therapeutics from Outperform to Mkt Perform
BTIG Research downgraded Keros Therapeutics from Buy to Neutral
Jefferies initiated coverage of Keros Therapeutics with a rating of Buy
Cantor Fitzgerald initiated coverage of Keros Therapeutics with a rating of Overweight
Discontinues Development of Cibotercept in PAH Announces Corporate Restructuring to Align Operations with Ongoing Strategic Priorities LEXINGTON, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros", the "Company" or "we") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced topline data from the TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arte
Keros Board Best Equipped to Oversee Strategic Review Process and Execute on Ultimate Outcome of that Process ADAR1's Disruptive and Self-Serving Campaign Stands to Jeopardize the Future Value Maximizing Potential of the Company Keros Urges Stockholders to Protect the Value of Their Investment by Voting "FOR" All Three of the Company's Highly Qualified Director Nominees LEXINGTON, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros", the "Company" or "we") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling o
ADAR1 Urges Board to Release Strategic Review Results Before, Not After, Annual Meeting AUSTIN, Texas, May 21, 2025 /PRNewswire/ -- ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1" or "We"), the largest stockholder of Keros Therapeutics (NASDAQ:KROS) ("Keros" or the "Company") with approximately 13.3% of the Company's outstanding shares, today announced that leading independent proxy advisory firm Institutional Shareholder Services Inc. ("ISS") has recommended that Keros stockholders WITHHOLD votes from incumbent directors Dr. Mary Ann Gray and Dr. Alpna Seth at the Company's upcoming Annual Meeting of Stockholders (the "Annual Meeting"), scheduled for June 4, 2025.
Files Investor Presentation and Issues Open Letter to Stockholders Urges Stockholders to Protect the Value of Their Investment by Voting "FOR" Each of the Company's Highly Qualified Director Nominees LEXINGTON, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros", the "Company" or "we") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today filed an investor presentation with the U.S. Securities and Exchange Commission (the "SEC") and issue
AUSTIN, Texas, May 12, 2025 /PRNewswire/ -- ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1"), the largest stockholder of Keros Therapeutics (NASDAQ:KROS) ("Keros" or the "Company") with approximately 13.3% of the Company's outstanding shares, today released an investor presentation outlining its rationale for withholding votes on the re-election of Dr. Mary Ann Gray and Dr. Alpna Seth to the Keros Board of Directors at the Company's upcoming Annual Meeting of Stockholders, scheduled for June 4, 2025. The presentation can be viewed here. About ADAR1 Capital Management ADAR1 Capital Management is an SEC-registered investment manager based
LEXINGTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that Keros' Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the Bank of America 2025 Global Healthcare Conference on Tuesday, May 13, 2025 at 8:00 p.m. Eastern time. A live audio webcast of the fireside chat presentation will be available at https://
Responds to Recent Public Stockholder Communications Urges Stockholders to Protect Their Investment by Voting "FOR" the Company's Highly Qualified Director Nominees LEXINGTON, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros", the "Company" or "we") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today issued the following statement in response to the misleading press release issued by ADAR1 Capital Management ("ADAR1") regarding K
Announces Intention to Withhold Votes for Directors Dr. Mary Ann Gray and Dr. Alpna Seth AUSTIN, Texas, May 8, 2025 /PRNewswire/ -- ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1"), the largest stockholder of Keros Therapeutics (NASDAQ:KROS) ("Keros" or the "Company") with approximately 13.3% of the Company's outstanding shares, today released a public letter to fellow Keros stockholders outlining its concerns with the Company's capital allocation decisions, strategic direction, and prolonged underperformance. In the letter, ADAR1 details the Company's alarming clinical results for two of its three drug candidates — KER-012 and KER-065
LEXINGTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today reported financial results for the quarter ended March 31, 2025. "In the first quarter, we reported initial topline results from the Phase 1 clinical trial of KER-065 that met key objectives and yielded valuable insights. These findings position us well as we prepare to engage with regulators with the aim
Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process LEXINGTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that its Board of Directors (the "Board") has determined to initiate a formal review process to evaluate strategic alternatives to maximize stockholder value for the Company. In connection with this determination, th
LEXINGTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today reported financial results for the quarter ended March 31, 2025. "In the first quarter, we reported initial topline results from the Phase 1 clinical trial of KER-065 that met key objectives and yielded valuable insights. These findings position us well as we prepare to engage with regulators with the aim
Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process LEXINGTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that its Board of Directors (the "Board") has determined to initiate a formal review process to evaluate strategic alternatives to maximize stockholder value for the Company. In connection with this determination, th
Trial achieved key objectives for safety, tolerability, pharmacokinetics and pharmacodynamicsClinical data from this trial, together with preclinical data, support the therapeutic potential of KER-065 for broad impact in Duchenne muscular dystrophy ("DMD") and other neuromuscular indicationsKeros plans on advancing KER-065 into a Phase 2 clinical trial in DMD, subject to positive regulatory interactionKeros to host a conference call and webcast today, March 31, 2025, at 8:00 a.m. ET LEXINGTON, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutic
LEXINGTON, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2024. "The efforts over the past year by the team at Keros have positioned us to continue to advance our promising pipeline of novel therapeutics," said Jasbir S. Seehra, Ph.D., Chair and Chief
Keros will host an update call and webcast today, December 12, 2024, at 8:00 a.m. ET LEXINGTON, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that it has voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patient
LEXINGTON, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today reported financial results for the quarter ended June 30, 2024. "Keros continued to build upon the progress of all programs across our pipeline in the second quarter of 2024, as evidenced by our recent positive regulatory and data updates from the elritercept (KER-050) program," said Jasbir S. Seehra, Ph.D
Elritercept continued to demonstrate a durable transfusion independence in lower-risk myelodysplastic syndromes, including in patients with high transfusion burden Durable clinical responses were associated with improvements in patient-reported measures of fatigueData from ongoing Phase 2 clinical trial in myelofibrosis continue to demonstrate that elritercept can not only ameliorate ineffective hematopoiesis and address cytopenias, but also provide broader clinical benefit, as supported by observed reductions in spleen volume and improved total symptom scoresKeros will host a corporate update call and webcast today, June 17, 2024, at 8:00 a.m. ET LEXINGTON, Mass., June 17, 2024 (GLOBE NE
LEXINGTON, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß"), today announced that the Company will host a corporate update conference call and webcast on Monday, June 17, 2024 at 8:00 a.m. Eastern time. "I am pleased to announce that Keros received positive feedback from the U.S. Food and Drug Administration regarding the KER-050 (elritercept) myelodysplastic syndromes ("MDS"
LEXINGTON, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today provided a business update and reported financial results for the quarter ended March 31, 2024. "Keros remained focused on clinical execution and continued to make strong progress across our pipeline in the first quarter of 2024," said Jasbir S. Seehra, Ph.D., President and Chief Executive Officer. "We look
KER-050 (elritercept) achieved durable transfusion independence in lower-risk MDS, including in patients with high transfusion burdenDurable clinical responses were associated with improvements in patient-reported measures of fatigueBiomarker data demonstrate that KER-050 treatment has potential to reduce NT-proBNP a measure of cardiac stressPreliminary findings from ongoing Phase 2 clinical trial in myelofibrosis demonstrate that KER-050 can not only ameliorate ineffective hematopoiesis and address cytopenias, but also provide broader clinical benefit seen through reduction of spleen size and improved symptomsKeros will be hosting a conference call and webcast today, December 11, 2023, at 8
LEXINGTON, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced the appointment of Yung H. Chyung, M.D., as Keros' Chief Medical Officer, effective as of November 1, 2024. "We are thrilled to welcome Yung to Keros and look forward to leveraging his development and TGF-ß superfamily expertise as we continue to advance our clinical programs," said Chair and Chi
LEXINGTON, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that it appointed Jean-Jacques Bienaimé to its Board of Directors, effective June 1, 2024. "On behalf of the Board, we are delighted to welcome Jean-Jacques to Keros during this pivotal phase of our growth," said President and Chief Executive Officer Jasbir Seehra, Ph.D. "Jean-Jacques is a deeply
LEXINGTON, Mass., April 19, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today announced that it appointed Alpna Seth, Ph.D., to its Board of Directors, effective May 1, 2023. "Dr. Seth's deep industry experience and expertise in drug development, global operations and product launches will be an invaluable addition to our Board of Directors," said President and Chief Executive Officer Jasbir Seehra, Ph.D. "We a
LEXINGTON, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced the appointment of Christopher Rovaldi as Keros' Chief Operating Officer, effective as of February 1, 2022. Mr. Rovaldi previously served as a consultant to Keros. "We are excited to welcome Mr. Rovaldi to the executive team as Chief Operating Officer," said Jasbir S. Seehra, Ph.D., Chief Executive Officer of Keros. "This addition allows us to benefit
LEXINGTON, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced that it appointed Mary Ann Gray, Ph.D., to its Board of Directors. "We are delighted to welcome Dr. Gray to Keros’ Board of Directors,” said President and Chief Executive Officer Jasbir Seehra, Ph.D. "Her deep experience guiding both growing and commercial-stage companies as a board member, coupled with her scientific and financia